AAPS PharmSci 360 2026:EpiVax首席科学官谈IND申报毒理研究中动物实验与动物数据的取舍
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
EpiVax首席科学官Vibha Jawa在AAPS PharmSci 360上指出,IND申报毒理研究是否需要动物实验因模态而异。单克隆抗体因已有充分数据和明确靶点,申办方可减少动物实验;免疫调节靶点、基因治疗及ADC因各自毒性风险仍可能需要动物模型。器官芯片等人体相关模型要替代动物实验,须围绕使用场景完成类似生物标志物的资格认定。
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Vibha Jawa, PhD, chief scientific officer at EpiVax, spoke with PharmTech at AAPS PharmSci 360 in New Orleans about the use of animal studies in new modalities, such as monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), specifically as they pertain to investigation new drug (IND) toxicology. Organ-on-chip and other human-relevant models, as well as new approach methodologies (NAMs), may one day replace animal studies, but Jawa says it depends on the modality. Jawa participated in presentation discussions on animal data during the event.
Jawa stresses that modalities differ sharply. Because mAbs have the most legacy knowledge and the best-understood targets, sponsors with enough of their own data can often run fewer animal studies. That changes, however, for immunomodulatory targets, where unexpected interactions with the immune system may require bringing some animal work back, Jawa says. Gene therapies still need animal models because safety must be assessed comprehensively, including biodistribution and systemic interactions with tissues, not only immunogenicity that ex vivo human models can reproduce. ADCs can draw on antibody experience to reduce testing, but the linker and small-molecule payload carry their own toxicities that in vitro and ex vivo assays may miss, so animal models may still be needed to track analytes and how they degrade.
There is a common myth about microphysiological systems that states that the more sophisticated the model, the more regulators will favor it, Jawa explains. To replace an animal study, she says, a model must answer the specific target-interaction or safety question being asked. Qualification resembles biomarker qualification and centers on context of use. Sponsors should confirm the science is robust and the right cells and receptors are present, that the model captures variability across human donors so results can inform clinical trials, and that benchmarks are relevant and cover all components of the tissue being reproduced.
About the Speaker
Vibha Jawa, PhD, chief scientific officer at EpiVax, a bioinformatics company in Providence, Rhode Island, that designs better vaccines and optimizes biologics to reduce immunogenicity risk. Before joining EpiVax, Jawa spent 5 years leading a translational group at Bristol Myers Squibb and earlier worked in translational drug development at Merck and Amgen.
Related to this article
November 13th, 2026
This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
November 9th, 2026
CPHI Award winner, Pauline van der Wijst-Janssen, PhD, product development manager and global technical lead at DFE Pharma, explains excipient variability and excipients’ role in continuous manufacturing.
November 9th, 2026
Pauline van der Wijst-Janssen, PhD, of DFE Pharma, won the CPHI Pharma Award for Future Leader. In this interview with PharmTech, she provides advice for scientists looking to advance to leadership roles.
November 6th, 2026
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains how her team managed the study’s strict −80 °C handling requirement, quality release, and site readiness, and how the Almac Adapt approach can apply beyond this program.
November 5th, 2026
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
November 5th, 2026
Vivek Gupta of Duquesne University explains at AAPS PharmSci 360 why device decisions can't wait and why excipient makers must test beyond drug molecules.
November 4th, 2026
Impurity deficiencies in submissions are remarkably consistent. Subathra Ramamoorthy, Veranova, explains how to catch them before agency filing.
November 17th, 2026
Cole and Jaenisch explain where pharma should keep manual checks, how to vet AI skills in hires, and why self-taught AI risks GMP.
来源:PharmTech Quality Systems · pharmtech.com





